Balanced news tone
News Sentiment
UPB sentiment intelligence
Upstream Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
48 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-6.9% over one week, +12.2% over four weeks, trend inactive, and below fair value.
ETFs Investing in Upstream Bio, Inc. Stocks
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
-6.9%
Price reacting lower
Trend fit
Trend inactive
12.2% over four weeks
Fair value
-53.7%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
27
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Seeking Alpha
Direct company coverage
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Seeking Alpha
GlobeNewswire
Direct company coverage
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 15:30
- Source
- GlobeNewswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
MT Newswires
Direct company coverage
Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 14 May 2026 10:20
- Source
- MT Newswires
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Zacks Investment Research
Direct company coverage
Should I buy Upstream Bio, Inc. (UPB)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Zacks Investment Research
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Feb 2026 08:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB)
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 12 Feb 2026 08:00
- Source
- Seeking Alpha
simplywall.st
Direct company coverage
Assessing Upstream Bio (UPB) Valuation After Recent Share Price Volatility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- simplywall.st
Market source
Direct company coverage
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- Market source
Trefis
Direct company coverage
Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Feb 2026 08:00
- Source
- Trefis
Investing.com
Direct company coverage
Upstream Bio stock tumbles after mixed Phase 2 asthma trial results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Feb 2026 08:00
- Source
- Investing.com
simplywall.st
Direct company coverage
Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jan 2026 08:00
- Source
- simplywall.st
MarketBeat
Direct company coverage
Upstream Bio (UPB) Stock Price, News & Analysis $UPB
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Oct 2024 01:44
- Source
- MarketBeat